Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...

Epsilogen and TigaTx have not disclosed the financial terms of the deal. Credit: RealPeopleGroup via Getty Images. UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that ...

Taken together, these findings demonstrate that interferon triggers PARP14-mediated ADP-ribosylation in p62 bodies, which requires an active ubiquitin-proteasome system. Interferon induces the ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

If both genetic parents are Rh-negative, their children will be, too. The pregnant parent should have their blood type, including Rh factor, tested and antibody screening done if indicated as part of ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

It moves around looking for damaged mitochondria, and when it finds them, it creates a protein called ubiquitin that signals the body to get rid of them. When that PINK1 protein mutates ...

Dr. James Hansen, a Yale Cancer Center researcher, and his team discovered that using an antibody related to lupus they can breach the tumor and trigger an immune response to fight it. He says ...

New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...